Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.43 |
| ▸ | SRC | P12931 | 13/20 | 0.43 |
| ▸ | KDR | P35968 | 13/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.43 |
| ▸ | EGFR | P00533 | 12/20 | 0.43 |
| ▸ | HCK | P08631 | 12/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.43 |
| ▸ | MTOR | P42345 | 12/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 12/20 | 0.43 |
| ▸ | PRKDC | P78527 | 12/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.43 |
| ▸ | RET | P07949 | 6/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147544 | 0.80 | ABL1 (0.41) | ABL1SRCKDRPIK3CDEGFR | |
| SCHEMBL868687 | 0.80 | ABL1 (0.58) | ABL1SRCKDRPIK3CDEGFR | |
| SCHEMBL14243160 | 0.77 | CHEK1 (0.37) | ABL1SRCKDRPIK3CDEGFR | |
| SCHEMBL30071117 | 0.72 | RET (0.41) | KDRRET | |
| SCHEMBL22494449 | 0.72 | MTOR (0.47) | ABL1SRCKDRPIK3CDEGFR | |
| SCHEMBL407871 | 0.70 | ADK (0.46) | SRCKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30104023 | 0.70 | SRC (0.48) | ABL1SRCKDRPIK3CDEGFR | |
| SCHEMBL22037128 | 0.69 | MEN1 (0.41) | SRCRET | |
| SCHEMBL16375259 | 0.67 | SRC (0.44) | ABL1SRCKDRPIK3CDEGFR | |
| SCHEMBL8975509 | 0.66 | ADK (0.74) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | ABL1 3937/4885SRC 1597/4885KDR 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.